<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ullrich <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> and Bethlem <z:hpo ids='HP_0003198'>myopathy</z:hpo> are skeletal muscle diseases that are due to mutations in the genes encoding collagen VI, an extracellular matrix protein forming a microfibrillar network that is particularly prominent in the endomysium of skeletal muscle </plain></SENT>
<SENT sid="1" pm="."><plain>Myoblasts from patients affected by Ullrich <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> display functional and ultrastructural <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> alterations and <z:mp ids='MP_0006042'>increased apoptosis</z:mp> due to inappropriate opening of the permeability transition pore, a <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> inner membrane channel </plain></SENT>
<SENT sid="2" pm="."><plain>These alterations could be normalized by treatment with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi>, a widely used <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> that desensitizes the permeability transition pore independently of calcineurin inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we report the results of an open pilot trial with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> in five patients with collagen VI <z:hpo ids='HP_0003198'>myopathies</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Before treatment, <z:hpo ids='HP_0000001'>all</z:hpo> patients displayed <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> dysfunction and increased frequency of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, as determined in muscle biopsies </plain></SENT>
<SENT sid="5" pm="."><plain>Both of these pathologic signs were largely normalized after 1 month of oral <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> administration, which also increased <z:mp ids='MP_0000750'>muscle regeneration</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>These findings demonstrate that collagen VI <z:hpo ids='HP_0003198'>myopathies</z:hpo> can be effectively treated with drugs acting on the pathogenic mechanism downstream of the genetic lesion, and they represent an important proof of principle for the potential therapy of <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic diseases</z:e> </plain></SENT>
</text></document>